Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19691220 | 0.84 | SMYD3 (0.61) | SMYD3HDAC3 | |
| SCHEMBL3195105 | 0.84 | CRBN (0.68) | SMYD3HDAC3 | |
| SCHEMBL4394998 | 0.83 | SMYD3 (0.52) | SMYD3HDAC3 | |
| SCHEMBL3190474 | 0.82 | SMYD3 (0.57) | SMYD3HDAC3 | |
| SCHEMBL29567045 | 0.82 | SMYD3 (0.57) | SMYD3HDAC3 | |
| Hydrochloric Acid SCHEMBL4399720 | 0.82 | SMYD3 (0.51) | SMYD3HDAC3 | |
| SCHEMBL3193145 | 0.81 | SMYD3 (0.71) | SMYD3HDAC3 | |
| SCHEMBL19701263 | 0.81 | SMYD3 (1.00) | SMYD3HDAC3 | |
| Hydrochloric Acid SCHEMBL28849276 | 0.81 | SMYD3 (0.56) | SMYD3HDAC3 | |
| SCHEMBL7089091 | 0.81 | SMYD3 (0.60) | SMYD3HDAC3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20190241569-A1 | 3-(ARYL OR HETEROARYL) METHYLENEINDOLIN-2-ONE DERIVATIVES AS INHIBITORS OF CANCER STEM CELL PATHWAY KINASES FOR THE TREATMENT OF CANCER | BOSTON BIOMEDICAL INC (US) | 2019-08-08 | — | — | US | disclosed |
| US-20190241550-A1 | HETEROCYCLIC SUBSTITUTED-3-HETEROARYLIDENYL-2-INDOLINONE DERIVATIVE | BOSTON BIOMEDICAL INC (US) | 2019-08-08 | — | — | US | disclosed |
| US-20160075697-A1 | HETEROCYCLIC SUBSTITUTED-3-HETEROARYLIDENYL-2-INDOLINONE DERIVATIVE | DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) | 2016-03-17 | — | — | US | disclosed |
| US-20160075697-A1 | HETEROCYCLIC SUBSTITUTED-3-HETEROARYLIDENYL-2-INDOLINONE DERIVATIVE | DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) | 2016-03-17 | — | — | US | disclosed |
| US-20160031888-A1 | 3-(ARYL OR HETEROARYL) METHYLENEINDOLIN-2-ONE DERIVATIVES AS INHIBITORS OF CANCER STEM CELL PATHWAY KINASES FOR THE TREATMENT OF CANCER | BOSTON BIOMEDICAL, INC. (US) | 2016-02-04 | — | — | US | disclosed |
| US-20160031888-A1 | 3-(ARYL OR HETEROARYL) METHYLENEINDOLIN-2-ONE DERIVATIVES AS INHIBITORS OF CANCER STEM CELL PATHWAY KINASES FOR THE TREATMENT OF CANCER | BOSTON BIOMEDICAL, INC. (US) | 2016-02-04 | — | — | US | disclosed |
| US-20160031888-A1 | 3-(ARYL OR HETEROARYL) METHYLENEINDOLIN-2-ONE DERIVATIVES AS INHIBITORS OF CANCER STEM CELL PATHWAY KINASES FOR THE TREATMENT OF CANCER | BOSTON BIOMEDICAL, INC. (US) | 2016-02-04 | — | — | US | disclosed |
| EP-2970206-A1 | 3-(ARYL OR HETEROARYL) METHYLENEINDOLIN-2-ONE DERIVATIVES AS INHIBITORS OF CANCER STEM CELL PATHWAY KINASES FOR THE TREATMENT OF CANCER | Boston Biomedical, Inc. (US) | 2016-01-20 | — | — | EP | disclosed |
| US-9227962-B2 | Heterocyclic substituted-3-heteroarylidenyl-2-indolinone derivative | BOSTON BIOMEDICAL, INC. (US) | 2016-01-05 | — | — | US | disclosed |
| US-9227962-B2 | Heterocyclic substituted-3-heteroarylidenyl-2-indolinone derivative | BOSTON BIOMEDICAL, INC. (US) | 2016-01-05 | — | — | US | disclosed |
| US-9227962-B2 | Heterocyclic substituted-3-heteroarylidenyl-2-indolinone derivative | BOSTON BIOMEDICAL, INC. (US) | 2016-01-05 | — | — | US | disclosed |
| WO-2014160401-A1 | 3-(ARYL OR HETEROARYL) METHYLENEINDOLIN-2-ONE DERIVATIVES AS INHIBITORS OF CANCER STEM CELL PATHWAY KINASES FOR THE TREATMENT OF CANCER | BOSTON BIOMEDICAL, INC. (US) | 2014-10-02 | — | — | WO | disclosed |
| WO-2014160401-A1 | 3-(ARYL OR HETEROARYL) METHYLENEINDOLIN-2-ONE DERIVATIVES AS INHIBITORS OF CANCER STEM CELL PATHWAY KINASES FOR THE TREATMENT OF CANCER | BOSTON BIOMEDICAL, INC. (US) | 2014-10-02 | — | — | WO | disclosed |
| US-20140275076-A1 | HETEROCYCLIC SUBSTITUTED-3-HETEROARYLIDENYL-2-INDOLINONE DERIVATIVE | BOSTON BIOMEDICAL, INC. | 2014-09-18 | — | — | US | disclosed |
| US-20140275076-A1 | HETEROCYCLIC SUBSTITUTED-3-HETEROARYLIDENYL-2-INDOLINONE DERIVATIVE | BOSTON BIOMEDICAL, INC. | 2014-09-18 | — | — | US | disclosed |
| US-20140275076-A1 | HETEROCYCLIC SUBSTITUTED-3-HETEROARYLIDENYL-2-INDOLINONE DERIVATIVE | BOSTON BIOMEDICAL, INC. | 2014-09-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160075697-A1 | HETEROCYCLIC SUBSTITUTED-3-HETEROARYLIDENYL-2-INDOLINONE DERIVATIVE | CYP2C9, DHRS9, HTR3B | SMYD3 822/4885HDAC3 51/4885 |
| US-20140275076-A1 | HETEROCYCLIC SUBSTITUTED-3-HETEROARYLIDENYL-2-INDOLINONE DERIVATIVE | CYP2C9, DHRS9, HTR3B | SMYD3 822/4885HDAC3 51/4885 |
| US-20190241569-A1 | 3-(ARYL OR HETEROARYL) METHYLENEINDOLIN-2-ONE DERIVATIVES AS INHIBITORS OF CANCER STEM CELL PATHWAY KINASES FOR THE TREATMENT OF CANCER | MAP3K2, MAP3K1, MAP3K3 | SMYD3 2518/4885HDAC3 550/4885 |
| US-20190241550-A1 | HETEROCYCLIC SUBSTITUTED-3-HETEROARYLIDENYL-2-INDOLINONE DERIVATIVE | CYP2C9, DHRS9, HTR3B | SMYD3 822/4885HDAC3 51/4885 |
| US-20160031888-A1 | 3-(ARYL OR HETEROARYL) METHYLENEINDOLIN-2-ONE DERIVATIVES AS INHIBITORS OF CANCER STEM CELL PATHWAY KINASES FOR THE TREATMENT OF CANCER | MAP3K19, MAP3K2, MAP3K3 | SMYD3 3034/4885HDAC3 562/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.